Virginijos Černiūtės odos ligų kabinetas, UAB - financials and debts

Company age: 26 y. 1 mo.

Update

Virginijos Černiūtės odos ligų kabinetas - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 68,653 74,259 81,037 96,003 110,453 130,206 147,922 173,065
Profit before tax 50,218 52,911 60,065 72,912 88,250 104,916 122,474 154,550
Net profit 50,214 52,908 60,062 72,912 88,250 104,916 122,474 154,550
Equity 53,281 56,094 63,258 76,167 91,967 108,633 126,191 158,740
Liabilities 202 136 206 397 704 812 732 826
Non-current assets 2,232 1,288 1,355 834 834 834 834 701
Current assets 51,251 54,942 62,109 75,730 91,664 108,447 126,050 158,745
Total assets 53,483 56,230 63,464 76,564 92,498 109,281 126,884 159,446
Taxes paid
STI taxes - - - - - 14,878 17,407 18,887
Financial indicators
Revenue change y/y +15.2% +8.2% +9.1% +18.5% +15.1% +17.9% +13.6% +17.0%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 93.9% 94.1% 94.6% 95.2% 95.4% 96.0% 96.5% 96.9%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 94.2% 94.3% 94.9% 95.7% 96.0% 96.6% 97.1% 97.4%
Profit margin Net profit margin. Shows the overall profitability of the company. 73.1% 71.2% 74.1% 75.9% 79.9% 80.6% 82.8% 89.3%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 73.1% 71.3% 74.1% 75.9% 79.9% 80.6% 82.8% 89.3%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 25,745 24,753 27,012 32,001 36,818 43,402 49,307 83,073

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Virginijos Černiūtės odos ligų kabinetas - Social security debts

From To Debt, €
2025-01-16 2025-02-11 0.16
2024-12-22 2024-12-26 0.18
2024-12-17 2024-12-20 0.18
2024-11-18 2024-12-11 0.20
2024-10-16 2024-11-11 0.22
2024-09-17 2024-10-08 0.22
2024-08-19 2024-09-11 0.12
2024-07-16 2024-08-12 0.12
2023-12-18 2023-12-26 5.44
2023-11-16 2023-12-11 5.44
2023-10-17 2023-11-09 5.44
2022-02-17 2022-03-13 0.13
2022-01-28 2022-02-13 0.14
2022-01-18 2022-01-20 65.64
2021-12-16 2021-12-21 66.15
2021-11-08 2021-11-14 0.23

Virginijos Černiūtės odos ligų kabinetas - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company Virginijos Černiūtės odos ligų kabinetas is: 1 €

From To Overdue, €
2026-06-18 2026-09-02 0.58
2026-02-21 2026-02-21 0.58
2026-02-03 2026-02-16 0.58
2026-01-31 2026-02-02 0.39
2026-01-14 2026-01-19 30.13
2025-05-17 2025-05-19 18300.0
2025-04-03 2025-04-23 18298.11
2025-01-14 2025-02-10 0.11
2024-08-14 2025-01-13 0.01

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Virginijos Cerniutes odos ligu kabinetas, UAB (code 151429967) is a private limited liability company engaged in medical specialists activities. In 2025, the company generated revenue of €173.1K and net profit of €154.6K, resulting in a profit margin of 89.3%. Performance strengthened over the last three years: revenue increased from €130.2K in 2023 to €147.9K in 2024 and €173.1K in 2025, while net profit rose from €104.9K to €122.5K and then to €154.6K. The balance sheet remained very conservative, with total assets of €159.4K, equity of €158.7K and liabilities of only €826 in 2025. The equity ratio was 99.6% and debt-to-equity stood at 0.01, indicating minimal leverage. Return on equity was 97.4% and return on assets was 96.9%, supported by asset turnover of 1.09x. Revenue per employee was €86.5K and profit per employee was €77.3K, pointing to strong operating productivity in 2025.